Vincerx Pharma Net Interest Income Over Time
| VINC Stock | USD 0.80 0.04 5.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vincerx Pharma Performance and Vincerx Pharma Correlation. Vincerx |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Interest Income Analysis
Compare Vincerx Pharma and related stocks such as Spero Therapeutics, Bolt Biotherapeutics, and Coherus BioSciences Net Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 303 K | 1.1 M | 1.3 M | 401 K | (1.6 M) | (1.5 M) | 3.9 M | 4.5 M | 4.8 M |
| BOLT | 193 K | 193 K | 193 K | 193 K | 193 K | 193 K | 193 K | 193 K | 193 K | 524 K | 199 K | 281 K | 2.2 M | 6.2 M | 7.1 M | 7.5 M |
| CHRS | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (9.6 M) | (9.7 M) | (17.6 M) | (21.2 M) | (23 M) | (32.5 M) | (40.5 M) | (36.5 M) | (34.7 M) |
| APLT | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | 3 K | (1.6 M) | 93 K | 559 K | 555 K | 685 K | 1.4 M | 1.6 M | 1.7 M |
| LYRA | 36 K | 36 K | 36 K | 36 K | 36 K | 36 K | 36 K | 36 K | 36 K | 213 K | 82 K | 102 K | 1 M | 4.1 M | 4.7 M | 4.9 M |
| STTK | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | 1.2 M | 549 K | 625 K | 1.6 M | 4.7 M | 5.4 M | 5.6 M |
| BCAB | (740 K) | (740 K) | (740 K) | (740 K) | (740 K) | (740 K) | (740 K) | (740 K) | (740 K) | (1.5 M) | (1.3 M) | 347 K | 1.6 M | 5.7 M | 6.6 M | 6.9 M |
| MNPR | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 48.3 K | 103.2 K | 98.9 K | 81.9 K | 24 K | 21.2 K | 343.6 K | 395.2 K | 414.9 K |
| SNTI | 88 K | 88 K | 88 K | 88 K | 88 K | 88 K | 88 K | 88 K | 88 K | 88 K | 88 K | 11 K | 1.7 M | 3.6 M | 4.1 M | 4.3 M |
| PCSA | (245.4 K) | (245.4 K) | (245.4 K) | (245.4 K) | (245.4 K) | (245.4 K) | (245.4 K) | (53.9 K) | (142.9 K) | (25.1 K) | (277.9 K) | 11.6 K | 101.2 K | 326.6 K | 375.5 K | 394.3 K |
| LVTX | (78 K) | (78 K) | (78 K) | (78 K) | (78 K) | (78 K) | (78 K) | (78 K) | (78 K) | (78 K) | (294 K) | (625 K) | 257 K | 3 M | 3.4 M | 3.6 M |
| RZLT | (4.1 K) | (4.1 K) | (4.1 K) | (4.1 K) | (4.1 K) | (4.1 K) | (1.6 K) | (688.2 K) | (4.9 M) | 188 K | (312 K) | (1.7 M) | 4.2 M | 4.9 M | 5.6 M | 5.9 M |
| XOMA | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (3.9 M) | (1.2 M) | (922 K) | (1.9 M) | (1.8 M) | (461 K) | 0.0 | (569 K) | (654.4 K) | (687.1 K) |
| TARA | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 237 K | 1.1 M | 2.9 M | 3.3 M | 3.5 M |
| SRZN | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 72 K | 781 K | 2.3 M | 2.7 M | 2.8 M |
Vincerx Pharma and related stocks such as Spero Therapeutics, Bolt Biotherapeutics, and Coherus BioSciences Net Interest Income description
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.My Equities
My Current Equities and Potential Positions
| Vincerx Pharma | VINC |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.8
Check out Vincerx Pharma Performance and Vincerx Pharma Correlation. For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Vincerx Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.